转移性结直肠癌全身治疗试验必备患者特征共识
BACKGROUND: Patient characteristics and stratification factors are key features influencing trial outcomes. However, there is substantial heterogeneity in reporting of patient characteristics and use of stratification factors in phase 3 trials investigating systemic treatment of …
要点
- 推荐纳入14项基线特征,包括年龄、体能状态、原发灶位置与切除、既往治疗、转移部位及分子标志物等。
- 确定5项最关键分层因素:RAS/BRAF突变状态、体能状态、原发灶侧别和仅肝转移。
- 纳入这些特征和分层可提高试验结果解读性并促进跨研究比较。
核心结论
- 共识提供了转移性结直肠癌III期全身治疗试验应纳入的最小基线患者特征集和分层因素集。
主要发现
- 推荐纳入14项患者特征:年龄、体能状态、原发肿瘤位置、原发肿瘤切除、既往化疗、转移部位数量、仅肝转移、肝脏受累、转移灶手术切除、同时性与异时性转移、(K)RAS和BRAF突变状态、微卫星不稳定性/错配修复状态及既往治疗线数。
- 认为5项患者特征是最相关的分层因素:RAS/BRAF突变状态、体能状态、原发肿瘤侧别和仅肝转移。
关键数值与推荐
- 推荐纳入的14项基线患者特征和5项分层因素详见原文列表。
临床怎么用
- 在设计转移性结直肠癌III期全身治疗试验方案和最终报告时纳入上述特征和分层,可提高试验结果解读性并促进跨研究比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient characteristics and stratification factors are key features influencing trial outcomes. However, there is substantial heterogeneity in reporting of patient characteristics and use of stratification factors in phase 3 trials investigating systemic treatment of metastatic colorectal cancer (mCRC). We aimed to develop a minimum set of essential baseline characteristics and stratification factors to include in such trials. METHODS: We performed a modified, two-round Delphi survey among international experts with wide experience in the conduct and methodology of phase 3 trials of systemic treatment of mCRC. RESULTS: Thirty mCRC experts from 15 different countries completed both consensus rounds. A total of 14 patient characteristics were included in the recommended set: age, performance status, primary tumour location, primary tumour resection, prior chemotherapy, number of metastatic sites, liver-only disease, liver involvement, surgical resection of metastases, synchronous versus metachronous metastases, (K)RAS and BRAF mutation status, microsatellite instability/mismatch repair status and number of prior treatment lines. A total of five patient characteristics were considered the most relevant stratification factors: RAS/BRAF mutation status, performance status, primary tumour sidedness and liver-only disease. CONCLUSIONS: This survey provides a minimum set of essential baseline patient characteristics and stratification factors to include in phase 3 trials of systemic treatment of mCRC. Inclusion of these patient characteristics and strata in study protocols and final study reports will improve interpretation of trial results and facilitate cross-study comparisons.
引用
- Goey KKH, Sørbye H, Glimelius B, et al. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018. PMID: 29936065. doi:10.1016/j.ejca.2018.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。